Greywolf Therapeutics

About:

We are advancing novel antigen modulation technology that controls T cells to guide the immune system.

Website: http://www.greywolftherapeutics.com/

Top Investors: Andera Partners, Earlybird Venture Capital, Oxford Science Enterprises, Intermediate Capital Group, British Patient Capital

Description:

Many cancers and other diseases are caused, or resist treatment, because T cells can't recognize or target cells correctly.​ We're progressing first-in-class antigen modulators through the clinic, developed to treat disease by controlling T cell activation. Our technology modulates antigen presentation, flicking a switch inside cells to alter their appearance to the immune system.​ This approach marks a fundamental shift in how we treat people living with autoimmune disorders, cancers and infectious diseases.